Clinical Trial Imaging 2023 Industry Report Potential Growth, Share, Demand And Forecast to 2030
Clinical Trial Imaging Industry Overview
The
global clinical trial imaging market size was estimated at USD 1.14 billion in
2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.60%
from 2024 to 2030. The market growth is anticipated to be fueled by the growing
biotechnology and pharmaceutical sectors, coupled with rising investments in
research and development for the creation of new drugs aimed at treating
various diseases. Medical imaging plays a pivotal role in advancing the development
of innovative life science products.
Gather more insights about the market drivers, restrains and
growth of the Clinical
Trial Imaging Market
Despite
the ever-changing nature of the medical imaging industry, the biotechnology and
pharmaceutical industries are showing sustained growth. This is primarily due
to the increased investment in medical imaging companies, as well as the
occurrence of mergers and acquisitions that involve the incorporation of
cutting-edge imaging technologies to facilitate clinical trials for medical
devices.
Advancements
in technology are bringing substantial improvements to the collection,
evaluation, and submission of clinical trial imaging data. Technology-enabled
imaging, especially image analysis software, provides various benefits to
clinical studies, such as consistency, data accuracy, adaptability, and
compliance. For instance, image analysis software is used to direct and manage
a reader by analyzing imaging time points. In addition, the increased use of
imaging technology, along with the enhanced power of computing, is expected to
drive the usage of imaging in clinical trials. The Quantitative Imaging
Biomarkers Alliance (QIBA) protocol has come up with standardized methods and
imaging procedures with uniform procedures to be implemented for attaining
statistical and precise endpoints in clinical trials.
The
Covid-19 pandemic has adversely impacted the healthcare system in most
countries, leading to a disruption in medical studies, and research activities,
and reduced sponsorship for research involving clinical trials. The pandemic
hampered the clinical trial timeline as numerous ongoing studies were delayed
and planned studies were cancelled. Unfavorable changes in regulations and
guidelines, supply chain disruption, recruitment challenges for clinical
trials, fear of viral spread, and shutting down of most manufacturers during
lockdown have adversely impacted the market. However, introducing virtual
imaging trials during the COVID-19 pandemic is expected to open new avenues for
adopting these devices. The development of advanced computational models helps
better assess CT and radiography images, which are expected to help in the
early diagnosis of COVID-19 patients. The market has witnessed a bounce back by
2022 Q2 due to increased R&D activities and improvement in supply and
distribution channels.
Many
patents have been filed in the realm of enhancing image evaluation and
capturing. In addition, imaging core lab provider’s offer patented technologies
that are anticipated to assist pharmaceutical companies in reducing their
development timelines. As an example, IXICO provides a diagnostic tool called
Assessa, which enhances decision-making in clinical trials for conditions
related to memory, including schizophrenia, Parkinson's, and Alzheimer's
disease, as well as neurological disorders such as dementia and cognitive
impairment.
However, the high cost of machinery and their installation, and the enormous
cost of clinical trials may limit the market growth during the forecast
periods. Advancements in technology are bringing substantial improvements to
the collection, evaluation, and submit clinical trial imaging data. Technology-enabled
imaging especially image analysis software provides various benefits to
clinical studies such as consistency, data accuracy, adaptability as well as
compliance. For instance, image analysis software is used to direct and manage
a reader via analysis of imaging time points.
Browse through Grand View Research's Medical Devices Industry
Research Reports.
•
The global mobile
stroke unit market size was valued at USD 35.80 million in 2023 and is
projected to grow at a CAGR of 5.2% from 2024 to 2030. Rising incidence of
strokes increased focus on early treatment of stroke patients are driving the
demand for efficient and timely stroke care services.
•
The global brain
tumor diagnosis and therapeutics market size
was valued at USD 3.11 billion in 2023 and is projected to grow at a CAGR of
7.1% from 2024 to 2030. The growing launches of brain tumor therapeutics
products and the rise in cancer awareness for brain tumor medications drive the
market over the forecast period.
Clinical Trial Imaging Market Segmentation
Grand
View Research has segmented the clinical trial imaging market on the basis of
on service, modality, application, end-use and region:
Clinical Trial Imaging Service Outlook (Revenue, USD Million, 2018
- 2030)
• Clinical Trial Design and Consultation Services
• Reading and Analytical Services
• Operational Imaging Services
• System and Technology Support Services
• Project and Data Management
Clinical Trial Imaging Modality Outlook (Revenue, USD Million,
2018 - 2030)
• Computed Tomography
• Magnetic Resonance Imaging
• X-Ray
• Ultrasound
• Optical Coherence Tomography (OCT)
• Others
Clinical Trial Imaging Application Outlook (Revenue, USD Million,
2018 - 2030)
• NASH
• CKD
• Diabetes
• Cardiovascular Diseases
• Ophthalmology
• Musculoskeletal
• Oncology
• Gastroenterology
• Pediatrics
• Others
Clinical Trial Imaging End-use Outlook (Revenue, USD Million, 2018
- 2030)
• Biotechnology and Pharmaceutical companies
• Medical Devices Manufacturers
• Academic and Government Research Institutes
• Contract Research Organizations (CROs)
• Others
Clinical Trial Imaging Regional Outlook (Revenue, USD Million,
2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o India
o China
o Japan
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait
Order
a free sample PDF of the Clinical Trial
Imaging Market Intelligence Study, published by Grand View Research.
Key Companies profiled:
• IXICO plc
• Navitas Life Sciences
• Resonance Health
• ProScan Imaging
• Radiant Sage LLC
• Medpace
• Biomedical Systems Corp
• Cardiovascular Imaging Technologies
• Intrinsic Imaging
• BioTelemetry
Recent Developments
•
In March 2023, Clario launched a cloud-based image viewer specifically for
clinical trials. This innovation aims to streamline medical image analysis and
improve its accessibility within the clinical research context
•
In May 2023, Cleerly has partnered with ProScan Imaging to provide personalized
solutions for cardiac health, which involve analyzing and devising treatment
strategies for cardiovascular issues. The partnership is expected to leverage
Cleerly's AI-powered platform to examine coronary CT angiography (CCTA) images
Comments
Post a Comment